Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient
International Journal of Molecular Sciences · 31.03.2024 · 25 (7) · 3919
DOI: 10.3390/ijms25073919 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 31.03.2024. Verfasst von Ching-Chi Hsu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Board of Directors, Wizcare Medical Corporation Aggregate, Taichung 404, Taiwan. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, Chung Shan Medical University Hospital, Taichung, Taiwan, Chung Shan Medical University, Taichung, Taiwan.
Themen: Demenz
Abstract (Originalsprache)
The delineation of biomarkers and neuropsychiatric symptoms across normal cognition, mild cognitive impairment (MCI), and dementia stages holds significant promise for early diagnosis and intervention strategies. This research investigates the association of neuropsychiatric symptoms, evaluated via the Neuropsychiatric Inventory (NPI), with cerebrospinal fluid (CSF) biomarkers (Amyloid-β42, P-tau, T-tau) across a spectrum of cognitive states to enhance diagnostic accuracy and treatment approaches. Drawing from the National Alzheimer’s Coordinating Center’s Uniform Data Set Version 3, comprising 977 individuals with normal cognition, 270 with MCI, and 649 with dementia. To assess neuropsychiatric symptoms, we employed the NPI to understand the behavioral and psychological symptoms associated with each cognitive category. For the analysis of CSF biomarkers, we measured levels of Amyloid-β42, P-tau, and T-tau using the enzyme-linked immunosorbent assay (ELISA) and Luminex multiplex xMAP assay protocols. These biomarkers are critical in understanding the pathophysiological underpinnings of Alzheimer’s disease and its progression, with specific patterns indicative of disease stage and severity. This study cohort consists of 1896 participants, which is composed of 977 individuals with normal cognition, 270 with MCI, and 649 with dementia. Dementia is characterized by significantly higher NPI scores, which are largely reflective of mood-related symptoms (p < 0.001). In terms of biomarkers, normal cognition shows median Amyloid-β at 656.0 pg/mL, MCI at 300.6 pg/mL, and dementia at 298.8 pg/mL (p < 0.001). Median P-tau levels are 36.00 pg/mL in normal cognition, 49.12 pg/mL in MCI, and 58.29 pg/mL in dementia (p < 0.001). Median T-tau levels are 241.0 pg/mL in normal cognition, 140.6 pg/mL in MCI, and 298.3 pg/mL in dementia (p < 0.001). Furthermore, the T-tau/Aβ-42 ratio increases progressively from 0.058 in the normal cognition group to 0.144 in the MCI group, and to 0.209 in the dementia group (p < 0.001). Similarly, the P-tau/Aβ-42 ratio also escalates from 0.305 in individuals with normal cognition to 0.560 in MCI, and to 0.941 in dementia (p < 0.001). The notable disparities in NPI and CSF biomarkers among normal, MCI and Alzheimer’s patients underscore their diagnostic potential. Their combined assessment could greatly improve early detection and precise diagnosis of MCI and dementia, facilitating more effective and timely treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Board of Directors, Wizcare Medical Corporation Aggregate, Taichung 404, Taiwan.
- International Intercollegiate Ph.D. Program, National Tsing Hua University, Hsinchu 300, Taiwan.
- Center for Health Data Science, Department of Medical Research, Chung Shan Medical University Hospital, Taichung 402, Taiwan.
- Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.
- Center for Traditional Medicine, Taipei Veterans General Hospital, Taipei 112, Taiwan.
- Institute of Traditional Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.
ORCID-Profile: Eric S Lin, Ching-Mao Chang, James Cheng-Chung Wei
Förderung
- NIA NIH HHS
- Chung Shan Medical University Hospital, Taichung, Taiwan
- Chung Shan Medical University, Taichung, Taiwan
Zitieren
APA
Hsu, C. C., Wang, S. I., Lin, H. C., Lin, E. S., Yang, F. P., Chang, C. M., & Wei, J. C. (2024). Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient. International Journal of Molecular Sciences, 25(7), 3919. https://doi.org/10.3390/ijms25073919
Vancouver
Hsu CC, Wang SI, Lin HC, Lin ES, Yang FP, Chang CM, et al. Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient. International Journal of Molecular Sciences. 2024;25(7):3919. doi:10.3390/ijms25073919
BibTeX
@article{Hsu2024,
author = {Hsu, Ching-Chi and Wang, Shiow-Ing and Lin, Hong-Chun and Lin, Eric S and Yang, Fan-Pei and Chang, Ching-Mao and Wei, James Cheng-Chung},
title = {Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {7},
pages = {3919},
doi = {10.3390/ijms25073919}
}
EUVIMED